These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 10965399)
1. Tolcapone: more than meets the eye? Deleu D; Hanssens Y Am J Health Syst Pharm; 2000 Aug; 57(16):1534. PubMed ID: 10965399 [No Abstract] [Full Text] [Related]
2. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder". Moroz G; Magni G; Fava M J Clin Psychopharmacol; 2000 Apr; 20(2):285. PubMed ID: 10770481 [No Abstract] [Full Text] [Related]
3. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Henry C; Wilson JA Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299 [No Abstract] [Full Text] [Related]
9. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats. Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I J Pharm Pharmacol; 1995 Jun; 47(6):539-42. PubMed ID: 7674141 [TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Jorga K; Fotteler B; Heizmann P; Gasser R Br J Clin Pharmacol; 1999 Oct; 48(4):513-20. PubMed ID: 10583021 [TBL] [Abstract][Full Text] [Related]
14. Tolcapone improves cognition and cortical information processing in normal human subjects. Apud JA; Mattay V; Chen J; Kolachana BS; Callicott JH; Rasetti R; Alce G; Iudicello JE; Akbar N; Egan MF; Goldberg TE; Weinberger DR Neuropsychopharmacology; 2007 May; 32(5):1011-20. PubMed ID: 17063156 [TBL] [Abstract][Full Text] [Related]
15. Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert. Khromova I; Rauhala P; Zolotov N; Männistö PT Neuroreport; 1995 May; 6(8):1219-22. PubMed ID: 7662912 [TBL] [Abstract][Full Text] [Related]
16. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Borges N Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845 [TBL] [Abstract][Full Text] [Related]
17. First COMT inhibitor approved for Parkinson's disease. Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322 [No Abstract] [Full Text] [Related]
18. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]